Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10721 (
c-kit
)
6,575
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Inflammatory myofibroblastic tumor
(
IMT
) is an uncommon mesenchymal solid tumor commonly documented in children and young adults. Here, we report a case of
IMT
in colon confirmed pathologically after laparoscopic anterior resection. A 35-year-old man presented with anal bleeding after defecation for 2 weeks. Colonoscopy demonstrated a mass with shallow ulceration in the central area and irregular margin accompanied by intact mucosa in the descending colon. Computer tomography showed a well-demarcated and homogenous solitary mass in the descending colon. We performed laparoscopic anterior resection. This case was diagnosed as
IMT
after microscopic examination. The tumor was composed of a proliferation of spindle-shaped cells arranged in the hyaline material with chronic inflammatory cells, composed mainly of plasma cells and lymphocytes. Immunohistochemically, tumor cells were positive for smooth muscle actin, and vimentin, and negative for desmin, CD117 (
c-kit
), anaplastic lymphoma kinase-1.
...
PMID:Inflammatory myofibroblastic tumor in colon. 2232 46
Soft tissue sarcoma(STS)is one of the rare and intractable cancers, and most types of STS are not sensitive to chemotherapy. Development of specific molecular target therapy for each type of STS is necessary. There are specific chromosome translocations in 20-30% of STS, but their products are mostly transcriptional factors, and target therapy for those factors are difficult to develop. Trabectedin is an alkylating agent and is also inhibit function of transcriptional factors, and shows efficacy for translocation-related sarcoma(TRS)such as myxoid liposarcoma. As molecular target therapies for gene mutations, success in molecular target therapy for
c-kit
and PDGFR mutation in GIST was followed by efficacy for rare sarcomas such as
IMT
or DFSP, but there are few developments in other sarcomas. STSs are frequently associated with angiogenesis and angiogenesis inhibitors such as pazopanib show some efficacy. Then immune checkpoint inhibitors also have been developed.
...
PMID:[Molecular Target Therapy for Soft Tissue Sarcoma]. 2869 33